Article
Medicine, Research & Experimental
Niels A. D. Guchelaar, Ruben A. G. van Eerden, Stefanie L. Groenland, Leni van Doorn, Ingrid M. E. Desar, Ferry A. L. M. Eskens, Neeltje Steeghs, Nielka P. van Erp, Alwin D. R. Huitema, Ron H. J. Mathijssen, Stijn L. W. Koolen
Summary: Therapeutic drug monitoring (TDM) for sorafenib is not of added value in daily clinical practice due to the limitations posed by toxicity that restrict dose escalations.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Biochemistry & Molecular Biology
Manuela Santonocito, Cristina Zappulla, Santa Viola, Luca Rosario La Rosa, Elena Solfato, Ilenia Abbate, Valeria Tarallo, Ivana Apicella, Chiara Bianca Maria Platania, Grazia Maugeri, Velia D'Agata, Claudio Bucolo, Sandro De Falco, Maria Grazia Mazzone, Francesco Giuliano
Summary: The study demonstrates that NaMESys-SOR eye drops can effectively deliver sorafenib to the retina and reduce proinflammatory and pro-angiogenic mediators in various animal models, showing potential for the treatment of proliferative retinopathies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Sergey Zyryanov, Irina Bondareva, Olga Butranova, Alexandra Kazanova
Summary: This study aimed to determine the population pharmacokinetic parameters of meropenem in preterm infants and evaluate the pharmacodynamic indices and covariates affecting pharmacokinetics. Analysis of demographic, clinical, and therapeutic drug monitoring data from 66 preterm newborns revealed that the median values for elimination rate and volume of distribution of meropenem were 0.31 1/h and 1.2 L respectively, and the median values for total clearance and elimination half-life were 0.22 L/h/kg and 2.33 h. Individualized Bayesian posterior models improved prediction quality compared to the population model.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Er-Min Gu, Ya-Nan Liu, Lvjun Pan, Yingying Hu, Xuemei Ye, Pingping Luo
Summary: This study developed a high throughput method to quantify sorafenib, regorafenib, cabozantinib and their active metabolites in plasma simultaneously. The method showed good specificity, precision, and accuracy, and was successfully applied to pharmacokinetic study.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Lea Bolcato, Anne Thiebaut-Bertrand, Francoise Stanke-Labesque, Elodie Gautier-Veyret
Summary: Isavuconazole (ISA), a triazole antifungal agent, is used for the treatment of invasive aspergillosis and mucormycosis. Therapeutic drug monitoring (TDM) is crucial for treatment efficacy, and this study investigated the inter- and intra-individual variability of ISA trough concentrations (Cmin) and identified the determinants involved, including dose, aspartate aminotransferase, and protein levels.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Chemistry, Analytical
Fangya Mu, Xinguang Zhou, Fang Fan, Zhiyu Chen, Guoyue Shi
Summary: In this study, a Vancomycin-specific fluorescent biosensor was developed and validated for rapid and accurate detection of Vancomycin using microdialysis sampling technique. The study successfully recorded subject-specific pharmacokinetics of Vancomycin in normal rabbits and those with chronic renal failure, demonstrating the feasibility of therapeutic drug monitoring in vivo. The research provides a scientific basis for an effective approach to monitor blood drug levels during clinical treatment.
ANALYTICA CHIMICA ACTA
(2021)
Article
Chemistry, Medicinal
He Yu, Raj K. Singh Badhan
Summary: This study highlights the importance of virtual therapeutic drug monitoring in Chinese and Caucasian cancer populations. Results showed significant inter-individual variability in drug concentrations, and dose adjustments were effective in achieving target therapeutic ranges. Conclusion: Virtual TDM can optimize treatments in challenging oncology population groups.
JOURNAL OF PHARMACEUTICAL SCIENCES
(2023)
Review
Infectious Diseases
Jitka Rychlickova, Vendula Kubickova, Pavel Suk, Karel Urbanek
Summary: The emerging resistance of Gram-negative bacteria is a global problem that has led to the reintroduction of colistin as a therapeutic option. However, there are still many questions regarding the safety and efficacy of colistin. This review summarizes the available literature on the use of colistin in critically ill patients, focusing on stability, pharmacokinetics, plasma concentration determination methods, and therapeutic drug monitoring benefits and limitations. Based on these findings, the gaps in knowledge are identified, and future research directions are suggested.
Article
Infectious Diseases
Maria Aquino, Maria Tinoco, Joana Bicker, Amilcar Falcao, Marilia Rocha, Ana Fortuna
Summary: Amikacin is the preferred antibiotic for treating Gram-negative infections in neutropenic oncology patients. However, there is a lack of population pharmacokinetic studies on amikacin in this patient population. This large-scale retrospective study investigated the effects of tumor diseases, chemotherapy, lag time, age, and renal function on amikacin pharmacokinetics in neutropenic cancer patients. The results showed that oncology patients received higher daily doses of amikacin and had increased drug clearance. Chemotherapy influenced amikacin pharmacokinetics and drug clearance decreased with longer lag time. The impact of aging on amikacin doses was stronger than chemotherapy. This research suggests that cancer patients may require higher initial doses of amikacin, especially within 30 days of starting chemotherapy.
Article
Infectious Diseases
Cindy Lau, Deborah Marriott, Jessica Bui, Melanie Figtree, Michael Gould, Adriana Chubaty, Yuen Su, Suman Adhikari, Pam Konecny, Kristi Kozierowski, Taylor Holland, Eliza Milliken, Ayesha Akram, Alexander Mcnamara, Yihui Sun, Sebastiaan Van Hal, Asad E. Patanwala, Aryan Shahabi-Sirjani, Timothy Gray, Chin Yen Yeo, Angela Netluch, Stephanie Halena, Marcelle Appay, Rozanna Alameddine, Fiona Yin, Quoc Nguyen, Mei-Yi So, Indy Sandaradura, Hannah Yejin Kim, Semun Galimam, Nicole Cerruto, Tony Lai, Timothy Gilbey, Kathryn Daveson, Stephanie E. Reuter, Jonathan Penm, Jan-Willem Alffenaar
Summary: This study aimed to evaluate linezolid toxicity in a large multicentre cohort and found that linezolid treatment-limiting toxicity remains a problem. TDM-guided dose optimisation significantly reduced the risk of toxicity and a treatment duration beyond 28 days was no longer significantly associated with toxicity.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Biophysics
Zupeng Yan, Zhenghan Shi, Yue Wu, Jingjiang Lv, Peixue Deng, Guang Liu, Zijian An, Ziyuan Che, Yanli Lu, Jianzhen Shan, Qingjun Liu
Summary: As an efficient patient management tool, decentralized therapeutic drug monitoring provides new possibilities for adherence and health management in schizophrenia. A wireless smart lollipop system was used to study the temporal metabolism of clozapine in rat saliva, providing real-time, noninvasive drug tracking. The system achieved highly sensitive and efficient sensing performance, allowing continual salivary drug level monitoring with distinctive pharmacokinetics for different routes of drug administration. This noninvasive saliva analysis system has the potential for patient-centered and personalized pharmacotherapy and adherence management.
BIOSENSORS & BIOELECTRONICS
(2023)
Article
Pharmacology & Pharmacy
Ki-Young Huh, Se-jung Hwang, Sang-Yeob Park, Hye-Jung Lim, Mir-yung Jin, Jae-seong Oh, Kyung-Sang Yu, Jae-Yong Chung
Summary: The study evaluated the pharmacokinetic equivalence between SYO-1644 and Nexavar through a two-period trial, finding that a dose range between 120 and 125 mg of SYO-1644 achieved the highest proportion of bioequivalence.
Article
Pharmacology & Pharmacy
Mengmeng Jia, Qiwen Zhang, Zifei Qin, Dao Wang, Peng Liu, Jing Yang, Xiaojian Zhang
Summary: This study aimed to investigate an appropriate dosing regimen and assess the exposure-response relationships of posaconazole (PCZ) in children. The study found that the dosage of PCZ varied depending on the age and purpose of treatment in children. Lower PCZ concentrations were associated with unsuccessful prophylaxis, while higher PCZ concentrations were associated with positive clinical response in treatment. Factors such as age, inflammatory markers, liver function indicators, and co-administration with proton pump inhibitors significantly affected PCZ concentrations.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Chemistry, Medicinal
Changhee Ha, Hyun-Seung Lee, Eun Yeon Joo, Young-Min Shon, Seung Bong Hong, Dae-Won Seo, Soo-Youn Lee
Summary: The study investigated the therapeutic drug monitoring of Levetiracetam in Korean epilepsy patients, revealing a large inter-individual difference in its pharmacokinetics and its susceptibility to EIAEDs. There was a strong correlation between weight-adjusted Levetiracetam dosage and concentrations.
Article
Pharmacology & Pharmacy
Agnieszka Karbownik, Danuta Szkutnik-Fiedler, Tomasz Grabowski, Anna Wolc, Joanna Stanislawiak-Rudowicz, Radoslaw Jazwiec, Edmund Grzeskowiak, Edyta Szalek
Summary: This study evaluated the potential pharmacokinetic drug-drug interactions between sorafenib and morphine, finding that morphine significantly increased plasma concentrations of sorafenib and its active metabolite, while sorafenib significantly increased the exposure to morphine and its metabolite, indicating potential clinical significance in cancer therapy with both improved response and increased risk of adverse effects.
Article
Oncology
Bruno Vincenzi, Andrea Napolitano, Marta Fiocco, Olivier Mir, Piotr Rutkowski, Jean-Yves Blay, Peter Reichardt, Heikki Joensuu, Elena Fumagalli, Spyridon Gennatas, Nadia Hindi, Margherita Nannini, Mariella Spalato Ceruso, Antoine Italiano, Giovanni Grignani, Antonella Brunello, Silvia Gasperoni, Tommaso De Pas, Giuseppe Badalamenti, Maria A. Pantaleo, Winan J. van Houdt, Nikki S. IJzerman, Neeltje Steeghs, Hans Gelderblom, Ingrid M. E. Desar, Johanna Falkenhorst, Marianna Silletta, Marta Sbaraglia, Giuseppe Tonini, Javier Martin-Broto, Peter Hohenberger, Axel Le Cesne, Robin L. Jones, Angelo P. Dei Tos, Alessandro Gronchi, Sebastian Bauer, Paolo G. Casali
Summary: This study evaluated the effect of high-dose imatinib on the survival of patients with KIT exon 9-mutated gastrointestinal stromal tumors. The results showed that increasing the dose from 400 mg/day to 800 mg/day did not lead to better survival outcomes.
CLINICAL CANCER RESEARCH
(2022)
Editorial Material
Immunology
Tarek Assi, Olivier Mir
Article
Oncology
Charlotte Le Roy, Cecile Le Pechoux, Claire Alapetite, Ratislav Bahleda, Carine Ngo, Charles Honore, Matthieu Faron, Axel Le Cesne, Olivier Mir, Christine Haie-Meder, Cyrus Chargari, Antonin Levy
Summary: Non-operable scalp cutaneous angiosarcoma patients face a scarcity of effective treatments. However, curative-intent definitive sequential IMRT and plesiobrachytherapy have shown promising results in two elderly patients, providing a non-invasive therapeutic option for locally advanced presentation.
Review
Orthopedics
Charles Court, Sylvain Briand, Olivier Mir, Cecile Le Pechoux, Thierry Lazure, Gilles Missenard, Charlie Bouthors
Summary: Chordoma is a rare and slow-growing malignant tumor mainly located in the sacrum and spine. Late clinical diagnosis and histologic diagnosis are necessary for treatment. Surgical resection is the most effective treatment, but patients should be prepared for potential neurologic sequelae.
ORTHOPAEDICS & TRAUMATOLOGY-SURGERY & RESEARCH
(2022)
Article
Oncology
Francois Bertucci, Vincent Niziers, Alexandre de Nonneville, Pascal Finetti, Lena Mescam, Olivier Mir, Antoine Italiano, Axel Le Cesne, Jean-Yves Blay, Michele Ceccarelli, Davide Bedognetti, Daniel Birnbaum, Emilie Mamessier
Summary: This study investigated the impact of immunologic constant of rejection (ICR) on the prognostic assessment of early-stage soft-tissue sarcomas (STS). The results showed that ICR signature was associated with patient age, pathological type, and tumor depth, and remained independently associated with metastasis-free survival (MFS) in multivariate analysis. A prognostic clinicogenomic model was also built, integrating ICR, Complexity Index in Sarcomas (CINSARC), and pathological type, and different systemic therapies were suggested for each prognostic group.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Anastasios Kyriazoglou, Pieter Jespers, Vincent Vandecavaye, Olivier Mir, Bernd Kasper, Zsuzsanna Papai, Jean-Yves Blay, Antoine Italiano, Facundo Zaffaroni, Saskia Litiere, Axelle Nzokirantevye, Patrick Schoffski
Summary: This study evaluated the treatment response in gastrointestinal stromal tumors (GISTs) and compared different assessment methods. The results showed that cabozantinib is active in GIST patients who have been treated with imatinib and sunitinib. Furthermore, the study demonstrated the limitations of the traditional RECIST assessment method in capturing the response to tyrosine kinase inhibitors (TKIs) in GIST patients, emphasizing the importance of including density changes in the evaluation.
Article
Oncology
Nicolas Penel, Sylvie Bonvalot, Andre-Michel Bimbai, Alexandra Meurgey, Francois Le Loarer, Sebastien Salas, Sophie Piperno-Neumann, Christine Chevreau, Pascaline Boudou-Rouquette, Pascale Dubray-Longeras, Jean-Emmanuel Kurtz, Cecile Guillemet, Emmanuelle Bompas, Antoine Italiano, Axel Le Cesne, Daniel Orbach, Julien Thery, Marie-Cecile Le Deley, Jean-Yves Blay, Olivier Mir
Summary: This prospective nationwide cohort study aimed to investigate the outcomes of desmoid-type fibromatosis (DF), focusing on the prognostic value of CTNNB1 mutations. The results showed that CTNNB1 mutation profile was associated with unfavorable prognostic factors but was not a prognostic factor for event-free survival (EFS).
CLINICAL CANCER RESEARCH
(2022)
Article
Nutrition & Dietetics
Pascaline Boudou-Rouquette, Alexandre de Moura, Claudia Martinez-Tapia, Adolfo Gonzalez Serrano, Anne Chahwakilian, Anne Jouinot, Guillaume Ulmann, Galdric Orvoen, Clelia Chambraud, Jean-Philippe Durand, Philippe Caillet, Francois Goldwasser, Elena Paillaud, Florence Canoui-Poitrine
Summary: In older patients with cancer, a hypermetabolic state is significantly associated with the risk of early limiting toxicity (ELT), and a predictive model based on resting energy expenditure (REE) shows better discriminant ability compared to existing scoring systems.
CLINICAL NUTRITION
(2022)
Article
Oncology
Sarah Watson, Benjamin Verret, Stanislas Ropert, Julien Adam, Rastislav Bahleda, Sylvain Briand, Andrea Cavalcanti, Ali N. Chamseddine, Charles Court, Elie Fadel, Matthieu Faron, Leila Haddag-Miliani, Clemence Henon, Cecile Le Pechoux, Antonin Levy, Olaf Mercier, Carine Ngo, Charles Honore, Axel Le Cesne, Olivier Mir
Summary: The activity of single-agent gemcitabine in advanced angiosarcoma was evaluated in this study. The results showed that gemcitabine had clinically meaningful activity, especially in cardiac angiosarcoma and patients who had received prior treatments.
Review
Health Care Sciences & Services
E. Minvielle, A. Fierobe, A. Fourcade, M. Ferrua, M. di Palma, F. Scott, O. Mir
Summary: This study examines the use of patient-reported measures (PRMs) as quality indicators (QIs) for health policy purposes, focusing on the field of oncology. The research analyzed 61 articles and 19 websites/reports, identifying 29 patient-reported experience measures (PREMs) and 48 patient-reported outcome measures (PROMs) from multiple countries. The study found that there are still barriers to overcome before PRMs can be effectively used for health policy in oncology, and further research is needed to develop valid QIs on a national level.
Review
Biochemistry & Molecular Biology
Camille Tlemsani, Frederique Larousserie, Sixtine De Percin, Virginie Audard, Djihad Hadjadj, Jeanne Chen, David Biau, Philippe Anract, Benoit Terris, Francois Goldwasser, Eric Pasmant, Pascaline Boudou-Rouquette
Summary: This review provides an overview of histopathology, clinical presentation, molecular pathways, and potential new systemic treatments of high-grade chondrosarcomas (CS). Conventional, dedifferentiated, and mesenchymal CS are discussed. CS diagnosis involves radiological and histological data in conjunction with patient clinical presentations. The standard treatment for CS is wide en-bloc resection, but new therapeutic options are emerging based on improved understanding of CS molecular biology.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Alice Boileve, Laurence Albiges, Michel Ducreux, Eric Baudin, Alexandra Leary, Benjamin Besse, Julien Hadoux, David Malka, Andre Rieutord, Florian Scotte, Amandine Maulard, Olivier Mir
Summary: This study retrospectively investigated the safety of concomitant use of DOAC and anti-VEGF agents in cancer patients. The results showed that the use of DOAC was safe in selected patients treated with KI, but the safety with bevacizumab was unclear. More data are needed to establish guidelines for this specific group of patients.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Mickael Tordjman, Charles Honore, Amandine Crombe, Amine Bouhamama, Antoine Feydy, Laurent Dercle, Leila Haddag, Pierre-Alban Bouche, Carine Ngo, Axel Le Cesne, Jean-Yves Blay, Olivier Mir, Mehdi Brahmi, Charlotte Martin, Marie Karanian, Samy Ammari, Michele Kind, Virginie Audard, Francois Le Loarer, Behnam Rabiee, Antoine Italiano, Pascaline Boudou-Rouquette, David Biau, Corinne Balleyguier, Frederique Larousserie, Jean-Luc Drape, Fadila Mihoubi
Summary: This study demonstrated that imaging biomarkers can be used to predict long-term outcome in patients with synovial sarcomas. Strikingly, the presence of calcifications on CT scan is associated with favorable outcome and provides an incremental value over existing prognostic factors such as age, grade, and size.
EUROPEAN RADIOLOGY
(2023)
Meeting Abstract
Oncology
Cesar Serrano, Sebastian Bauer, David Gomez-Peregrina, Yoon-Koo Kang, Robin L. Jones, Piotr Rutkowski, Olivier Mir, Michael C. Heinrich, William D. Tap, Kate Newberry, Alexandra Grassian, Stephen G. Miller, Hongliang Shi, Patrick Schoffski, Maria A. Pantaleo, Margaret Von Mehren, Jonathan C. Trent, Suzanne George
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Marie-Cecile Le Deley, Jean-Yves Blay, Jennifer Wallet, Francois Bertucci, Emmanuelle Bompas, Thomas Brodowicz, Loic Chaigneau, Christine Chevreau, Emilie Decoupigny, Antoine Italiano, Bernadette Lieg-Atzwanger, Olivier Mir, Sophie Piperno-Neumann, Julien Thery, Axel Le Cesne, Nicolas Penel
JOURNAL OF CLINICAL ONCOLOGY
(2022)